Distribution Modernization Survey for Clinic and Hospital Customers

You are receiving this survey because you are involved in the care of patients receiving Hemlibra (emicizumab) and/or Glassia (alpha-1 proteinase inhibitor) through the Distribution Modernization (DM) project in Alberta. This survey is being done to evaluate DM and provide Canadian Blood Services with important information about clinic and hospital customers’ experiences to further improve the project. This feedback will also be included in a report to the Ministry of Health to help inform decisions on continuation of this project.

The DM project at Canadian Blood Services was started in October 2023 and currently involves delivery of Hemlibra and Glassia by Bayshore Pharmacy to patients in Alberta (most often to their homes). In addition to dispensing and delivering medications, Bayshore Pharmacy coordinates with patients’ medical providers, patient support programs, and Canadian Blood Services to make sure patients have the medications and supplies they need. The project provides Canadian Blood Services with dispensing data to help us better understand how these products are being used, and ensure patients have access to the best possible care.

Please note that this survey is only evaluating the Distribution Modernization project, with services provided by Bayshore Pharmacy. Patient support programs (e.g., OnePath, EasySTART, Innomar) are not being evaluated in this survey.

The survey should take you 10-15 minutes to complete and will be open until March 16, 2025. Thank you for participating and sharing your view with us.

Please provide your email address (optional)

Which of the following roles best describes you?

* required

Hematologist

Respirologist

Nurse

Medical Laboratory Technologist (MLT)

Other (please specify)

Which of the following products do the patients under your care take?

* required

Hemlibra (emicizumab)

Glassia (alpha-1 proteinase inhibitor)

Both Hemlibra and Glassia

N/A (please explain)

Where is your primary practice located?

* required

Hospital clinic

Community clinic

Transfusion Medicine Laboratory

Other (please specify)

Do you have hospital privileges allowing you to order/prescribe products through a transfusion medicine laboratory (i.e., blood bank)?

* required

Yes

N/A (please describe)

How many patients do you have enrolled with Bayshore Pharmacy to date?

* required

1-5

6-10

11 or more

N/A (please explain)

What is your main method of communication with Bayshore Pharmacy?

* required

Telephone

Text

Fax

Other (please specify)

On average, how often do you communicate with Bayshore Pharmacy?

* required

Daily or more frequently

Weekly

Monthly or less frequently

Never

Other (please specify)

Which question(s) do you most often contact Bayshore pharmacy for? Please select all that apply:

* required

Enrolling patients

Sending new or refill prescriptions

Drug information questions

Adverse reactions

Delivery arrangements/questions

Distribution Modernization program or process questions

Other (please specify)

10.

On a scale of 1-10 (where 1 is the least and 10 is the most), how satisfied are you with your communications with Bayshore Pharmacy?

* required

Please select one number below:

11.

On a scale of 1-10 (where 1 is the least and 10 is the most), how would you rate your overall experience with the Distribution Modernization project?

* required

Please select one number below:

12.

What elements of the Distribution Modernization project are working well for your patients and for you as their clinician?

* required

13.

Please describe any challenges you have experienced with the Distribution Modernization project with Bayshore Pharmacy. Please include if these challenges are ongoing, or if they have improved over the course of the pilot.

* required

14.

In your experience, how could the Distribution Modernization project be improved in the future?

* required

15.

Other comments/concerns:

* required